Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Autoimmune Diseases Research Model Developed to Clarify Antibody Mechanisms

By BiotechDaily International staff writers
Posted on 21 Jul 2013
Canadian scientists have devised a unique research model for the study of autoimmune diseases. The Montréal scientists are the first to find an approach to better understand two significant processes that enhance the quality of antibodies.

This study, conducted by researchers from the l'Institut de Recherches Cliniques de Montréal (IRCM; QB, Canada), led by Dr. Javier M. Di Noia in the immunity and viral infections research division, was published in the June 15, 2013, issue of the Journal of Immunology.

Dr. Di Noia’s team is evaluating B cells, a group of white blood cells known as lymphocytes whose major task is to make antibodies to fight against antigens. “Our project focused on two mechanisms that produce this wide variety of antibodies,” said Dr. Di Noia, director of the mechanisms of genetic diversity research unit at the IRCM. “Because both processes are initiated by the same enzyme known as AID [activation-induced deaminase], it had previously been very difficult to study them separately. We were able to identify, for the first time, a mouse model in which the mechanisms could be analyzed independently during an acute immune response.”

The two processes being studied are known as class switching and affinity maturation. Class switching is the mechanism that allows a B cell to generate diverse classes of antibodies, so that a single antibody can be used by several different parts of the immune system. Affinity maturation, on the other hand, is the process by which B cells produce antibodies with increasingly stronger bonds to antigens during an immune response.

“Since eliminating AID would in turn completely eliminate affinity maturation and class switching, we focused on an enzyme called UNG, which is also involved in both processes,” added Astrid Zahn, research associate in Dr. Di Noia’s laboratory and first author of the study. “When we analyzed mice lacking the UNG [uracil-DNA glycosylase] gene, we found that affinity maturation was normal but class switching was strongly reduced during acute immune responses, such as the response to immunization and against a viral infection.”

“While over 100 AID-deficient patients have been identified, it is striking that only a handful of patients are known to be UNG-deficient,” explained Dr. Zahn. “Our study, which shows that chronic antibody responses [those to environmental antigens] remain nearly normal without UNG, can explain why most UNG-deficient individuals are not detected among immunodeficient patients. Nevertheless, because we also found that acute antibody responses were significantly affected, we suspect that UNG-deficient people will, for example, respond very poorly to vaccination. In addition, as this work was conducted as part of a larger ongoing investigation of the complex relationship between AID and UNG, we believe that UNG might possibly act as a tumor-suppressor in B-cell lymphomas.”

“Until now, it was difficult to study the relative importance of class switching and affinity maturation, and the impact of these two mechanisms on immune responses,” concluded Dr. Di Noia. “Our study provides a novel model to study the contribution of these mechanisms in certain autoimmune diseases such as lupus and rheumatoid arthritis, or some infections like influenza.”

Related Links:

l'Institut de Recherches Cliniques de Montréal



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.